Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

(03) 9028 2888

clients@freshequities.com

Antisense Therapeutics Limited

Investor presentation - Antisense Therapeutics Limited

ASX:ANP

Antisense Therapeutics Limited

Health

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Read more

Market Cap

$120.55m

Price at Close

$0.21

4w avg. Volume

5.52m

4w avg. Turnover

$1.08m

Announcements
announcementt+2 movementdate
  • Appendix 2A

    Issued Capital

  • +19.05%

    15 Jan 2021

+19.05%

15 Jan 2021
  • Proposed issue of Securities - ANP

    Issued Capital

  • +19.05%

    15 Jan 2021

+19.05%

15 Jan 2021
  • Change of Registered Office and Principal Place of Business

    Company Administration

  • +18.92%

    14 Jan 2021

+18.92%

14 Jan 2021
  • Ceasing to be a substantial holder

    Shareholder Details

  • +11.11%

    11 Jan 2021

+11.11%

11 Jan 2021
  • Results of Annual General Meeting

    Notice Of Meeting

  • 0.00%

    18 Dec 2020

0.00%

18 Dec 2020
  • Annual General Meeting Chairman's Address

    Chairman's Address · Market sensitive

  • -13.33%

    17 Dec 2020

-13.33%

17 Dec 2020
  • 2020 Annual General Meeting Presentation

    Periodic Reports · Market sensitive

  • -13.33%

    17 Dec 2020

-13.33%

17 Dec 2020
  • EC grants Orphan Drug Designation for ATL1102 in DMD

    Progress Report · Market sensitive

  • +19.57%

    13 Dec 2020

+19.57%

13 Dec 2020
  • Receipt of R&D Tax Incentive payment

    Periodic Reports · Market sensitive

  • -4.00%

    07 Dec 2020

-4.00%

07 Dec 2020
  • Ceasing to be a substantial holder

    Shareholder Details

  • 0.00%

    03 Dec 2020

0.00%

03 Dec 2020
Market Data

Current Price

$0.21

52WK HIGH

$0.27

52WK LOW

$0.029

1YR RETURN

+176.32%

1YR RETURN VS. SECTOR

+137.63%

90 DAY RETURN

+68.00%

ASX RANK

811

/2,048

SECTOR RANK

70

/168

SHARES OUTSTANDING

574.06m
ASX:ANP

Antisense Therapeutics Limited

Health

Antisense Therapeutics Limited (ANP.ASX) is an Australian publicly traded biopharmaceutical drug discovery and development company whose mission is to create, develop and commercialize novel antisense therapeutics for a variety of drug candidates including Duchenne Muscular Dystrophy (DMD), Multiple Sclerosis (MS), and Acromegaly.

Read more

Market Cap

$120.55m

Price at Close

$0.21

4w avg. Volume

5.52m

4w avg. Turnover

$1.08m

ASX:ANP is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.